Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Leases: 2019-2024

Historic Current Leases for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $2.0 million.

  • Keros Therapeutics' Current Leases rose 24.82% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 24.82%. This contributed to the annual value of $2.0 million for FY2024, which is 96.82% up from last year.
  • According to the latest figures from FY2024, Keros Therapeutics' Current Leases is $2.0 million, which was up 96.82% from $1.0 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Current Leases registered a high of $2.0 million during FY2024, and its lowest value of $423,000 during FY2020.
  • Moreover, its 3-year median value for Current Leases was $1.0 million (2023), whereas its average is $1.1 million.
  • In the last 5 years, Keros Therapeutics' Current Leases plummeted by 47.22% in 2022 and then skyrocketed by 120.88% in 2023.
  • Keros Therapeutics' Current Leases (Yearly) stood at $423,000 in 2020, then surged by 103.78% to $862,000 in 2021, then plummeted by 47.22% to $455,000 in 2022, then surged by 120.88% to $1.0 million in 2023, then skyrocketed by 96.82% to $2.0 million in 2024.